Last reviewed · How we verify
T 614
At a glance
| Generic name | T 614 |
|---|---|
| Also known as | diprospan |
| Sponsor | Wen Zhang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA (PHASE4)
- The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment (PHASE4)
- The Clinical Efficacy of Immunomodulators in RA Patients (PHASE4)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (PHASE3)
- The Iguratimod Effect on Lupus Nephritis (IGeLU) (PHASE2)
- To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom (PHASE4)
- Iguratimod as Treatment for Refractory Lupus Nephritis (NA)
- Study of Iguratimod in Sjögren's Syndrome (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |